Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?

Edward S. Chambers1*, Douglas J. Morrison2 and Gary Frost1

1Faculty of Medicine, Nutrition and Dietetic Research Group, Section of Investigative Medicine, Hammersmith Campus, Imperial College London, UK
2Stable Isotope Biochemistry Laboratory, Scottish Universities Environmental Research Centre, University of Glasgow, East Kilbride, Glasgow, UK

In recent years, there has been a renewed interest in the role of dietary fibre in obesity management. Much of this interest stems from animal and human studies which suggest that an increased intake of fermentable fibre can suppress appetite and improve weight management. A growing number of reports have demonstrated that the principal products of colonic fermentation of dietary fibre, SCFA, contribute to energy homeostasis via effects on multiple cellular metabolic pathways and receptor-mediated mechanisms. In particular, over the past decade it has been identified that a widespread receptor system exists for SCFA. These G-protein-coupled receptors, free fatty acid receptor (FFAR) 2 and FFAR3 are expressed in numerous tissue sites, including the gut epithelium and adipose tissue. Investigations using FFAR2- or FFAR3-deficient animal models suggest that SCFA-mediated stimulation of these receptors enhances the release of the anorectic hormones peptide tyrosine tyrosine and glucagon-like peptide-1 from colonic L cells and leptin from adipocytes. In addition, the SCFA acetate has recently been shown to have a direct role in central appetite regulation. Furthermore, the SCFA propionate is a known precursor for hepatic glucose production, which has been reported to suppress feeding behaviour in ruminant studies through the stimulation of hepatic vagal afferents. The present review therefore proposes that an elevated colonic production of SCFA could stimulate numerous hormonal and neural signals at different organ and tissue sites that would cumulatively suppress short-term appetite and energy intake.

Recent longitudinal studies highlight that adults increase body weight gradually through middle age, with an average annual weight gain of approximately 0·5 kg (1,2). This accumulation of body weight has resulted in an increased prevalence of obesity and its associated co-morbidities, as obesity incidence rates are now above 20 % in most Western countries and represent a major public health burden (3). As a result, interventions that can be safely applied at the population level to prevent long-term weight gain would have major benefits to public health. It has been suggested that gradual adult weight gain can be the result of only a small habitual positive energy balance of 209·2–418·4 kJ/d (50–100 kcal/d) (4). Consequently, an improved understanding of the hormonal and neuronal signals that control appetite regulation may facilitate the development of novel dietary strategies that suppress energy intake and oppose a positive energy balance and long-term weight gain.

Epidemiological and experimental studies have consistently highlighted an inverse association between dietary fibre intake and body weight gain (5–7). Furthermore, an increased intake of dietary fibre has been associated with improved appetite regulation (8), thus making high-fibre diets an attractive strategy to reduce obesity levels. The current definition of dietary fibre (9) encompasses a diverse range of compounds that include both dietary fibre and dietary bioactive compounds.
of compounds with different chemical structures that influence their physiological effects. As a result, it has been proposed that dietary fibre can increase levels of satiation (the process that leads to the termination of eating) and satiety (the process that leads to inhibition of further eating after a meal has finished) by numerous mechanisms, depending on the natural properties of the ingested fibre. Evidence suggests that the fermentable component of some dietary fibres may be important in promoting appetite regulatory effects and improvements in weight management. Current Western diets contain energy-dense foods that are generally low in fibre (10–20 g/d) and high in sugars and fats. This is in marked contrast to the Palaeolithic diet, which contained >100 g/d dietary fibre, to which the human gastrointestinal (GI) system has evolved over several millennia. This ancestral diet was rich in indigestible plant material, which would have contained a large fermentable fibre component, and it has been suggested that the modern low-fibre diet fails to stimulate many satiation and satiety signals originating from the GI tract. Dietary fibre passes through the small intestine unaffected by digestive enzymes, and upon reaching the colon, anaerobic bacteria are able to degrade some of these dietary fibres via a fermentation process that yields energy for the resident micro-organisms. The fermentability of dietary fibre varies, with resistant starches, NSP and non-digestible oligosaccharides being principal fermentable substances. It has been estimated that the human gut microbiota consists of 10^13–10^14 micro-organisms and is composed of approximately 1000 different species of bacteria, which belong to three principal phyla: Bacteroidetes, Firmicutes and Actinobacteria. The main end-products of microbial fermentation are SCFA, heat and gases (CO₂, H₂ and CH₄). SCFA are classified as carboxylic acids that contain less than six carbon atoms. The most abundant (about 95%) SCFA present in the human colon lumen are acetate (C₃), propionate (C₄) and butyrate (C₄), in the approximate molar ratio 60 : 20 : 20. The precise production of SCFA is difficult to measure in human subjects due to the inaccessibility of the colonic lumen. Furthermore, the formation of different SCFA can vary considerably between individuals due to large differences in gut microbial composition and activity. Bacterial species that belong to the Bacteroidetes phylum mainly produce acetate and propionate, whereas the Firmicutes phylum primarily produces butyrate. An investigation that measured SCFA directly from the human gut lumen reports that the highest concentrations are present in the proximal colon (about 120 mM/kg luminal contents) and these levels decrease distally through the colon, revealing that SCFA are rapidly absorbed across the apical and basolateral membranes of colonocytes. It is estimated that fermentation of dietary fibre can yield 400–600 mM SCFA/d, which is equivalent to about 5–10% of human energy requirements and, furthermore, it has been consistently demonstrated in animals and human subjects that the amount of dietary fibre consumed has a considerable effect on the concentration of SCFA produced in the large bowel. The aim of the present review is to evaluate the possible mechanisms that may explain how an elevated colonic production of SCFA could suppress short-term appetite responses and energy intake.

Central nervous system control of appetite and energy intake

The hypothalamus and the brainstem are the main central nervous system regions responsible for the regulation of appetite and energy intake. These brain areas integrate the complex peripheral hormonal and neuronal signals that represent the current physiological state of the body. The arcuate nucleus (ARC) within the hypothalamus senses hormones secreted into the peripheral circulation through a semipermeable blood–brain barrier. This nucleus contains two populations of neurons: (1) the orexigenic (appetite-stimulating) neuropeptide Y and agouti-related peptide and (2) the anorexigenic (appetite-suppressing) pro-opiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript. Within the brainstem, the nucleus of the solitary tract integrates neural signals derived from stimulation of vagal afferents in the gut and other visceral tissues in response to chemical, mechanical and hormonal stimuli. There are extensive reciprocal connections between the hypothalamus and the brainstem and appetite responses and energy intake are coordinated on the basis of the hormonal and neural signals received by both brain regions.

SCFA receptors and anorectic gut hormone release

In 2003, it was demonstrated that SCFA act as ligands for the previously orphaned G-protein-coupled receptors GPR41 and GPR43. These receptors have since been renamed free fatty acid receptor (FFAR) 3 and FFAR2, respectively. As G-protein coupled receptors, FFAR2 and FFAR3 are linked to heterotrimeric G-proteins attached to the cytoplasmic side of the receptor and stimulation of individual G-proteins triggers different cellular responses through the activation of specific secondary messenger cascades. FFAR2 couples to both Gαo (pertussis toxin-sensitive) and Gα₂-proteins (pertussis toxin-insensitive), whereas FFAR3 couples only to Gαo-proteins. Both FFAR2 and FFAR3 are activated by physiological concentrations of SCFA, although a preference of FFAR2 for acetate and propionate and of FFAR3 for propionate and butyrate has been reported. These receptors have been shown to be expressed not only in the gut epithelium but also in multiple tissue sites, including adipose tissue, immune cells, skeletal muscle and within the peripheral nervous system. A possible role for these receptors in energy intake regulation emerged with the identification that FFAR2 and FFAR3 are present on colonic endocrine L-cells. The L-cell is found at its highest density in the colonic epithelium and secretes the anorexigenic hormones peptide tyrosine tyrosine (PYY) and glucagon-like peptide (GLP)-1.

PYY is released into the circulation after food intake, with levels rising to a plateau after 1–2 h and remaining
elevated for up to 6 h \(^{(40)}\). Intravenous infusion of PYY to both lean and obese human subjects has been demonstrated to reduce energy intake \(^{(41,42)}\) and this anorexigenic effect is thought to be exerted via neuropeptide Y inhibition and POMC activation in the hypothalamic ARC \(^{(41,43)}\). Peripheral vagal afferents are also involved in the appetite-suppressive action of PYY; as the hormone has been shown to stimulate the activity of gastric vagal nerves and vagotomy was reported to abolish the effect of PYY on feeding responses \(^{(44,45)}\).

GLP-1 is primarily recognised as an incretin, but it also fulfills several criteria in order to be considered a satiety signal. Circulating levels of GLP-1 rise following a meal in proportion to energy intake and are low in the fasted state \(^{(46)}\). Furthermore, across a range of studies intravenous infusion of GLP-1 has been demonstrated to acutely reduce food intake in human subjects \(^{(47)}\). GLP-1 receptors are expressed in many regions throughout the hypothalamus, with high levels in the ARC \(^{(48)}\). Abolishing ARC neuronal signalling eliminates the inhibitory effect of GLP-1 on food intake and appetite \(^{(49)}\). Similar to PYY, the action of circulating GLP-1 on appetite-suppressive action \(^{(49)}\). It was found that FFAR2 enhances GLP-1 secretion by triggering an intracellular calcium response \(^{(50)}\). Evidence suggests that SCFA are capable of stimulating the release of PYY and GLP-1 \(^{(50,51)}\), as well as an increased number of colonic L-cells \(^{(52)}\). In human subjects, it has been shown that adding 24 g of the fermentable fibre oligofructose to a test meal significantly increased GLP-1 levels in the postprandial period \(^{(61)}\). This finding is supported by an investigation that revealed that feeding 16 g oligofructose/d for 2 weeks significantly lowered subjective hunger ratings, which was associated with increased PYY and GLP-1 release during a test meal \(^{(62)}\). Furthermore, in a longer-term investigation, overweight volunteers were given 21 g oligofructose/d or a placebo for 12 weeks and the fermentable fibre intervention group experienced significant weight loss compared with the placebo group, which was associated with enhanced PYY release and reduced self-reported energy intake during the supplementation period \(^{(63)}\). Recent reports have suggested that the amount of fermentable fibre consumed in the diet is critical to observe an effect on gut hormone release, as it was found that the supplementation of 16 g oligofructose/d, but not 10 g/d, for 13 d stimulated postprandial PYY and GLP-1 release \(^{(64)}\). This would suggest that high daily intakes of fermentable fibres may be needed to produce the colonic concentrations of SCFA required to modulate PYY and GLP-1 release. This is supported by a recent dose-escalation study in healthy human participants completing a 5-week supplementation period where the daily intake of oligofructose increased from 15, 25, 35, 45, 55 g/d each week and it was found that intake of fermentable fibre exceeding 35 g/d was needed to elevate post-prandial PYY release \(^{(65)}\). In summary, available evidence suggests that SCFA are capable of stimulating the anorectic gut hormones PYY and GLP-1 from colonic L-cells, primarily via the activation of FFAR2. Consequently, with a sufficiently high dietary intake, fermentable fibres can elevate anorectic gut hormone profiles, through an increased colonic production of SCFA.

**SCFA and digestive tract motility**


The GI tract contains mechanoreceptors and chemoreceptors that relay information to the central nervous system via vagal afferents, which contribute to the regulation of satiation and satiety \(^{(28)}\). It has been proposed that slowing the rate at which ingested food passes through the GI tract prolongs stimulation of these chemo- and mechanoreceptors, which in turn extends satiety following food intake \(^{(66,67)}\). For example, numerous studies have reported that delaying the gastric emptying of ingested food is associated with short-term effects on appetite and satiety measures \(^{(68,69)}\). The direct effect of luminal SCFA on colonic motility has been studied using *in vitro* and *in vivo* models. Squires *et al.* \(^{(70)}\) reported that large concentrations of SCFA decreased colonic contractile activity when infused in an isolated rat colon. However, *in vivo* studies performed in human subjects have failed to indicate that SCFA directly modulate colonic motility. Recently, it has been reported that in twenty healthy human volunteers...
intra-colonic infusion of a SCFA mixture had no direct effects on colonic motor activity, measured with perfused catheters and an electronic barostat(73), supporting a previous observation involving two human subjects(72). Nevertheless, SCFA may modulate motility of the upper digestive tract through the release of PYY and GLP-1. Cherbut et al. (51) observed that intraluminal infusion of SCFA into the rat colon significantly slowed gut transit rate. It was reported that the colonic infusion of SCFA released PYY in the peripheral circulation, suggesting that PYY could mediate the inhibitory effect of SCFA on gut motility. This hypothesis was supported by the finding that when colonic SCFA were administered following the immunoneutralisation of circulating PYY the effect of SCFA on gut transit rates was abolished. PYY is one of the hormones considered to mediate the 'ileal brake reflex', and studies have shown PYY to inhibit gastric emptying(73,74). In addition, it has been found that elevating circulating levels of GLP-1 can also slow rates of gastric emptying (73,79). Consequently, SCFA-stimulated release of PYY and GLP-1 from colonic L-cells may be capable of modifying appetite responses by delaying the gastric emptying of ingested foods and prolonging the stimulation of mechanoreceptors and chemoreceptors in the GI tract.

Hepatic metabolism of propionate

As previously mentioned, the largest concentrations of SCFA are found in the proximal colon, where SCFA are rapidly absorbed by colonocytes. Measurements in isolated colonocytes have shown that the majority of the energy demands of colonocytes (about 70%) are derived from oxidation of SCFA(77). SCFA that are not metabolised by colonocytes are released from the gut via the hepatic and portal vein system and measurements in human subjects have found that the molar fractions of acetate, propionate and butyrate change from approximately 60:20:10 in the colonic lumen to 70:20:10 in the portal vein(19) indicative of the preferential use of butyrate by mammalian colonocytes as an energy source(77,78). SCFA that are not metabolised by the liver then enter the peripheral circulation, where the approximate molar fraction is changed to 90:5:5 for acetate, propionate and butyrate, respectively(19). This demonstrates that the liver takes up a considerable amount of propionate from the circulation. Indeed, it has been estimated that about 90% of propionate in the peripheral circulation, and concentrations in human peripheral blood of 170, 4 and 8 μmol/l have been reported for acetate, propionate and butyrate, respectively(90). SCFA that do not undergo hepatic metabolism enter the peripheral circulation, and concentrations in human peripheral blood of 170, 4 and 8 μmol/l have been reported for acetate, propionate and butyrate, respectively(90). Furthermore, these hypophagic effects of elevating exogenous propionate in the portal vein are abolished with hepatic vagotomy or total liver denervation(85,86). However, caution must be taken when considering ruminants as models to study appetite regulation in human subjects, as marked differences in energy utilisation exist between species. Ruminants must synthesise their entire glucose requirements via hepatic gluconeogenesis and exogenous propionate accounts for approximately 80% of endogenous glucose production(87). It is therefore unsurprising that, as a major energy substrate, propionate availability provides such a potent satiety signal in ruminant species. While much less is known about the effect of propionate on glucose production in man, the vast majority of exogenous propionate is metabolised by the liver and a recent investigation using an innovative labelling strategy, in combination with localised in vivo 13C magnetic resonance spectroscopy, reported that elevating exogenous propionate supply to the human liver increased hepatic glucose production by 30%(88). As a key anabolic organ, which is estimated to contribute 20% of resting energy expenditure in human subjects(89), it is plausible that substantial changes in hepatic glucose production and storage could be sensed centrally to regulate feeding behaviour. An interesting area of future research would determine how increasing the concentrations of propionate produced in the human colon would alter hepatic intracellular signalling pathways related to energy status, and whether these changes to hepatic metabolic processes provide an anorectic neural signal to appetite-regulatory regions of the brain.

SCFA and leptin secretion

SCFA that do not undergo hepatic metabolism enter the peripheral circulation, and concentrations in human peripheral blood of 170, 4 and 8 μmol/l have been reported for acetate, propionate and butyrate, respectively(90). Furthermore, it has been demonstrated in human studies that elevating the fermentable fibre component of the diet raises SCFA levels in the peripheral blood(61,91–93), particularly concentrations of acetate. Circulating SCFA have been shown to interact with different peripheral organ and tissue sites. In particular, it has been demonstrated that SCFA have a major regulatory role in adipocyte function and metabolism(34,36,94) and are reported to stimulate leptin secretion(35,95). Circulating levels of leptin are proportional to fat mass and can cross the blood–brain barrier to induce an anorectic effect via the ARC, where both neuropeptide Y/agouti-related peptide and POMC/cocaine and amphetamine-regulated transcript neurons express leptin receptors(96). Leptin inhibits neuropeptide Y/agouti-related peptide neurons and activates POMC/cocaine and amphetamine-regulated transcript neurons(97), resulting in reduced energy intake. Leptin-deficient mice have been shown to exhibit hyperphagia and obesity, which can be reversed by leptin.
administration. In 2004, Xiong et al. reported that FFAR3 was expressed in adipocytes and that SCFA could stimulate leptin expression in both a mouse adipocyte cell line and mouse adipose tissue in primary culture. Furthermore, it was found in vivo that elevating circulating levels of propionate increased leptin levels in mice. Nevertheless, not all researchers have been able to detect FFAR3 in different adipose tissue sites, thus the role of FFAR3 in adipose tissue function is currently a contentious topic. It has been...
consistently reported that FFAR2 is abundantly expressed in white adipose tissue \(^{34-36}\) and suggested that FFAR2 may be responsible for stimulating leptin release from adipocytes. It was found that leptin secretion from wild-type adipocytes was increased by acetate, yet butyrate had no significant effect \(^{15}\). Owing to the different activation potencies of FFAR2 and FFAR3 to acetate \(^{29,30}\), this would imply that FFAR2 is responsible for triggering leptin secretion. Furthermore, leptin secretion from FFAR2 \(^{-/-}\) mice adipocytes was lower compared with wild-types. While acetate was also found not to secrete leptin from FFAR3 \(^{-/-}\) mice adipocytes, this was suggested to be due to a reduced expression of FFAR2 in these cells rather than the abolition of FFAR3 signalling. Finally, it has been demonstrated that the effects of FFAR2 on leptin release are due to Gi/o-protein signalling, rather than a G\(\alpha\)-protein-mediated mechanism, as leptin secretion by SCFA is prevented in the presence of pertussis-toxin, which inactivates Gi/o signal transduction \(^{29,30}\). In summary, studies indicate that circulating SCFA, particularly acetate and propionate, can promote leptin secretion from adipocytes via activation of FFAR2, thus providing an anorectic signal to appetite-regulatory neurons in the hypothalamic ARC.

### Direct central effects of acetate on hypothalamic control of appetite

As previously stated, acetate is the most abundant end product of colonic fermentation of dietary fibre and circulates at considerably greater concentration compared with propionate and butyrate. There is evidence to suggest that acetate can travel across the blood–brain barrier and enter the central nervous system \(^{100}\), raising the possibility that SCFA may have a direct effect on central appetite regulation. Using an intravenous and colonic infusion of \(^{11}\)C-acetate in mice and \(^{14}\)C-acetate in rats, \(^{29,30}\) this would imply that FFAR2 is responsible for stimulating appetite suppression. Many of these possible mechanisms (summarised in Fig. 1) would be strengthened with additional data from human studies, as the majority of the current available evidence to support a role of SCFA in appetite-regulation has been obtained from animal models, where direct translation into human subjects may be limited. Nevertheless, targeting the mechanisms through which SCFA suppress appetite through the development of novel dietary interventions that augment colonic SCFA production may be an effective strategy to improve appetite regulation and long-term weight management.

### Financial Support

The Section of Investigative Medicine, Imperial College is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology Capacity Building Award, an FP7-HEALTH- 2009- 241592 EuroCHIP grant and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. G. F. is supported by an NIHR senior investigator award. The work in SUERC is funded by the BBSRC and by a Scottish Government Strategic Partnership award in Food and Drink Science.

### Conflicts of Interest

None.

### Authorship

E. S. C. wrote the paper and had primary responsibility for final content. D. J. M. and G. F. were involved in refining the paper.

### References

8. Liu S, Willett WC, Manson JE et al. (2003) Relation between changes in intakes of dietary fiber and grain
Control of appetite and energy intake by SCFA